Exhibit 10.25

 

[g93132koi001.jpg]

 

Certain portions of this Exhibit have been omitted pursuant to a request for
confidentiality. Such omitted portions, which are marked with brackets [     ]
and an asterisk*, have been separately filed with the Securities and Exchange
Commission.

 

“Agreement Amendment No. 2”

 

[17 March, 2011]

 

Janssen Pharmaceutica N.V.

Turnhoutseweg 30

B-2340 Beerse

Belgium

 

Elan Drug Delivery, Inc.

3500 Horizon Drive

King of Prussia, PA 19046

USA

 

Dear Sirs

 

RE:                            License Agreement dated March 31, 1999 (the
“Agreement”), as amended by letter amendment of July 31, 2003, between Elan Drug
Delivery, Inc. (successor in interest in and to Elan Pharmaceutical Research
Corp., d/b/a Nanosystems(“EDDI”) and Elan Pharma International Limited (“EPIL”) 
(EDDI and EPIL collectively hereinafter referred to as “Elan”) and Janssen
Pharmaceutica N.V.  (“Janssen”)

 

Elan and Janssen hereby agree that with effect from July 31, 2009 this Agreement
Amendment No. 2 (“Agreement Amendment No. 2 Effective Date”) the Agreement shall
be amended as follows:

 

1.                                      All references in the Agreement to EPRC
shall read EDDI.  All references to NANO shall read Elan.

 

2.                                      Article 22             Elan contact
details only - shall be deleted and replaced with the following:

 

If to
Elan:                                                                                  
Elan Pharma International Limited

 

--------------------------------------------------------------------------------

 

 

EPIL Letter to Janssen and EDDI of 23 July 2009

 

Amendment No 2 to license dated 31 March 1999, as amended

 

Certain portions of this Exhibit have been omitted pursuant to a request for
confidentiality. Such omitted portions, which are marked with brackets [     ]
and an asterisk*, have been separately filed with the Securities and Exchange
Commission.

 

 

Monksland, Athlone, County Westmeath, Ireland

 

 

 

Attention:

Vice President & Legal Counsel

 

Telefax:

00 353 90 64 95402

 

 

With a copy to:

Elan Drug Delivery, Inc.

 

3500 Horizon Drive, King of Prussia, PA 19406,

 

USA

 

 

 

 

Attention:

President

 

Telefax:

001 610-313-5182

 

3.                                      Patent Schedules

 

3.1                               Exhibit A: Nano Patents shall be deleted and
replaced with Exhibit A:  Nano Patents — Updated January, 2011, attached hereto.

 

Exhibit B:  Selection Patents shall be deleted and replaced with Exhibit B
Selection Patents — Updated January 2011, attached hereto.

 

4.                                      Defined texts used in this Agreement
Amendment No. 2 shall have the meaning assigned to them in the Agreement unless
such terms are expressly defined in this Agreement Amendment No. 2.  All other
provisions of the Agreement not amended herein shall remain unchanged and in
full force and effect.

 

Yours faithfully,

 

 

 

Signed on behalf of:

 

Elan Pharma International Limited

 

 

 

/s/ William Daniel

 

Name:

William Daniel

 

Title:

Director

 

Date:

1 April 2011

 

 

Agreed and accepted for and on behalf of

Elan Drug Delivery, Inc. successor in interest in and to Elan Pharmaceutical
Research Corp., d/b/a Nanosystems

 

2

--------------------------------------------------------------------------------

 

Certain portions of this Exhibit have been omitted pursuant to a request for
confidentiality. Such omitted portions, which are marked with brackets [     ]
and an asterisk*, have been separately filed with the Securities and Exchange
Commission.

 

 

 

/s/ David Czekai

 

Name: David Czekai

 

Title: VP and GM

 

Date: 18 Apr 2011

 

 

 

Accepted for and on behalf of:

 

Janssen Pharamceutica N.V.

 

 

 

 

 

/s/ Ludo Lauwers

 

Name: Ludo Lauwers

 

Title: Senior Vice President, Site Management

 

Date: 17 March 2011

 

 

 

 

 

/s/ Dirk Collier

 

Member of the Board

 

 

3

--------------------------------------------------------------------------------

 

Certain portions of this Exhibit have been omitted pursuant to a request for
confidentiality. Such omitted portions, which are marked with brackets [     ]
and an asterisk*, have been separately filed with the Securities and Exchange
Commission.

 

Exhibit A: Nano Patents—Updated January, 2011

 

[*****]

 

4

--------------------------------------------------------------------------------

 

Certain portions of this Exhibit have been omitted pursuant to a request for
confidentiality. Such omitted portions, which are marked with brackets [     ]
and an asterisk*, have been separately filed with the Securities and Exchange
Commission.

 

[Exhibit B: Selection Patents—Updated July 31, 2009]

 

[*****]

 

5

--------------------------------------------------------------------------------